UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.21, sa.2, ss.24-28, 2011 (SCI-Expanded)
Although a large scale survey investigating the practice patterns of physicians for Chronic Myeloid Leukemia (CML) throughout Turkey is absent, there is an increasing enthusiasm on this subject after several years of experience with Tyrosine Kinase Inhibitors (TKI) therapy. Considering the problems in the management of CML patients, we can focus on deficiencies in the laboratory tests for diagnosis and monitoring, management of suboptimal response with imatinib therapy and conducting visit frequency of patients.